



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-772)

In re Application of:)
)
Somberg, et al.)
) Group Art Unit: 1651
Serial No.: 10/655,878)
) Examiner: TBA
Filed: September 5, 2003)
) Confirmation No.: 6857
For: Method for Detecting Transferase)
Enzymatic Activity)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

In regard to the above-identified patent application:


1. We are transmitting herewith the attached:
 - a. Transmittal Letter
 - b. Information Disclosure Statement
 - c. Form PTO-1449
 - d. Copies of Four Cited References
 - e. Return Receipt Postcard
2. With respect to additional fees:
☒ A. No additional fee is required.
☐ B. Attached is a check in the amount of \$_____.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the document(s) as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of May, 2004.

Date:

May 11, 2004

By:

Emily Miao
Reg. No. 35,285



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-772)

PATENT

In re Application of:)
)
Somberg, et al.)
) Group Art Unit: 1651
Serial No.: 10/655,878)
) Examiner: TBA
Filed: September 5, 2003)
) Confirmation No.: 6857
For: Method for Detecting Transferase)
Enzymatic Activity)
)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449 and copies¹ of the documents listed thereon. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

United States Patents

1. U.S. Patent No. 5,648,232 A (D.J. Squirrell).
2. U.S. Patent No. 6,319,898 B1 (Davies, et al.).

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

Foreign Documents

3. WO 02/48390 A2, published June 20, 2002.

Other Documents

4. Kapoor, et al., "Pyruvate Kinase of *Neurospora Crasse*. Effect of Various Ligands on the Rate of Inactivation by Protein Denaturants", *Can. J. Microbiol.*, 1972, Vol. 18, No. 8, pp. 1221-1232.


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: May 11, 2004


Respectfully submitted,



Emily Miao

Registration No. 35,285

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, Suite 3200
Chicago, Illinois 60606
Telephone: (312) 913-0001
Facsimile: (312) 913-0002

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Atty. Docket No. 03-772	Serial No. 10/655,878
	Applicant: Somberg, et al.	
	Filing Date: September 5, 2003	Group: 1651

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	1.	5,648,232 A	07/15/1997	D.J. Squirrell			
	2.	6,319,898 B1	11/20/2001	Davies, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	3.	WO 02/48390 A2	06/20/2002	WIPO-PCT				

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

	4.	Kapoor, et al., "Pyruvate Kinase of Neurospora Crasse. Effect of Various Ligands on the Rate of Inactivation by Protein Denaturants", <i>Can. J. Microbiol.</i> , 1972, Vol. 18, No. 8, pp. 1221-1232.						
--	----	--	--	--	--	--	--	--

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.